Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology
|
|
- Stuart Bell
- 7 years ago
- Views:
Transcription
1 Ann Surg Oncol (2015) 22: DOI /s ORIGINAL ARTICLE BREAST ONCOLOGY Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology M. Intra, MD 1, G. Viale, MD 2,3, J. Vila, MD 1, C. M. Grana, MD 4, A. Toesca, MD 1, O. Gentilini, MD 1, V. Galimberti, MD 1, P. Veronesi, MD 1,3, A. Luini, MD 1, N. Rotmensz, MSc 5, V. Bagnardi, MSc 5,6, D. Mattar, MD 1, and M. Colleoni, MD 7 1 Division of Breast Surgery, European Institute of Oncology, Milan, Italy; 2 Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; 3 University of Milan School of Medicine, Milan, Italy; 4 Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy; 5 Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; 6 Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy; 7 Division of Medical Senology, European Institute of Oncology, Milan, Italy ABSTRACT Purpose. This retrospective study aimed to determine the feasibility, accuracy, and recurrence rates of lymphoscintigraphy and the new sentinel lymph node biopsy (SLNB) for patients with ipsilateral breast tumor recurrences who were treated previously with conservative surgery and had negative SLNB results. Methods. The study was conducted at the European Institute of Oncology in Milan and included 212 patients with the diagnosis of operable local breast cancer recurrence. They had been treated previously with conservative surgery and showed negative SLNB results. They subsequently underwent additional breast surgery and a second SLNB between May 2001 and December Results. Preoperative lymphoscintigraphy demonstrated at least one new axillary sentinel lymph node (SLN) in 207 patients (97.7 %), whereas no drainage was observed in five patients (2.3 %). One or more SLNs were surgically removed from 196 of the 207 patients. Isolation of SLNs from the remaining 11 patients could not be accomplished. The success rate for the SLNB was 92.5 %. Extra-axillary drainage pathways were visualized in 17 patients (8 %). The annual axillary recurrence rate after a median followup period of 48 months was 0.8 %, and the cumulative incidence of axillary recurrence at 5 years was 3.9 %. Society of Surgical Oncology 2014 First Received: 29 October 2014; Published Online: 17 December 2014 M. Intra, MD mattia.intra@ieo.it Conclusions. A second SLNB should be considered for patients with operable local breast tumor recurrence who underwent conservative surgery and had negative SLNB results. The procedure is technically feasible and accurate for selected patients. Sentinel lymph node biopsy (SLNB) is the standard technique for axillary staging of patients with primary operable breast cancer and a clinically negative axilla because it avoids unwarranted axillary dissection and consequently reduces postoperative morbidity. 1 3 With widespread use of breast-conserving surgery (BCS) and increased accuracy of diagnostic imaging techniques, the rate of ipsilateral breast tumor recurrence (IBTR) within 10 years after BCS has been minimized to approximately 5 10 %. 4,5 However, optimum management of the axilla in IBTR patients previously treated with BCS who had negative SLNBs remains controversial. In a recent update of the American Society of Clinical Oncology (ASCO), the indications for SLNB for patients with early-stage breast cancer definitively were broadened. The guidelines indicate the feasibility and acceptable accuracy of SLNBs for patients who have undergone prior nononcologic axillary surgery, as corroborated by retrospective data. 6 However, no recommendations are made for patients who have previously undergone SLNB or ALND as a part of conservative breast cancer management. Therefore, ALND still is commonly used as the standard axillary treatment for IBTR after lumpectomy and negative SLNB results. 7 However, several studies have convincingly demonstrated acceptable second SLNB success rates and high
2 Re-operative Sentinel Node Biopsy in Locally Breast Relapse 2373 TABLE 1 Characteristics and results from the largest studies (C15 patients) of second sentinel lymph node biopsies for patients with ipsilateral breast tumor recurrences after previous breast-conserving surgery and sentinel node biopsy Author (year) n Median follow-up after sslnb (mos) Success rate of sslnb % (n) Percentage of extra-axillary drainages % (n) No. of axillary recurrences n (%) Port et al. 10 (2007) (40/54) 5.5 (3) 0 Cox et al. 12 (2008) (45/56) 2.2 (1) 0 Schrenk et al. 16 (2008) (12/15) 14.3 (2) van der Ploeg et al. 11 (2010) (26/36) 47 (17) 0 Maaskant-Braat et al. 17 (2013) (22/41) 25 (10/41) Intra et al. 8 (2014) (196/212) 8 (17) 7 (3.3) n number of patients, sslnb second sentinel lymph node biopsy identification rates of subsequent SLN for patients with previous negative SLNB results To date, five retrospective studies of 15 or more IBTR patients previously managed with BCS and SLNBs have been published, demonstrating a variable rate of success for the second SLNB ranging from 72.2 to 80.4 % 10 12,16,17 (Table 1). A recent meta-analysis of 26 articles and case reports and one published abstract regarding repeated SLNBs for 692 patients with locally recurrent breast cancer showed high success rates for SLNB used for lymphatic mapping, identification of SLN, and acceptable identification of extraaxillary drainage for patients with previous axillary surgery. 18 In the current study, the feasibility and accuracy of lymphoscintigraphy and a second SLNB, the percentages and types of extra-axillary drainage, and recurrence rates were investigated in 212 patients with IBTR and previous negative SLNBs. This study aimed to clarify whether second SLNB procedures are safe and feasible in selected cases of IBTR, to evaluate the accuracy of second SLNBs according to the number of axillary recurrences observed during the follow-up period, and to report long-term outcomes in terms of recurrence for patients with IBTR who underwent a second SLNB. MATERIAL AND METHODS Patient Population and Study Parameters The medical records of 212 IBTR patients previously treated with BCS who had negative SLNB results in their initial management between 1998 and 2010 were retrospectively analyzed. Of these patients, 185 had been treated at the European Institute of Oncology (EIO), and 27 had been treated elsewhere. All the patients had been treated for IBTR at the EIO between May 2001 and December At the initial surgery, the diagnosis for 185 patients (87 %) was invasive breast cancer, and the diagnosis for 27 patients (13 %) was ductal intraepithelial neoplasia (DIN). The patients who underwent mastectomy as a primary intervention, irrespective of the type of axillary surgery performed, those with clinical evidence of metastasis at the IBTR diagnosis, and those treated with ALND at the first surgery were excluded from the current analysis and will be subjects of future investigations. For the purpose of this study, IBTR was defined as biopsy-proven reappearance of DIN or invasive cancer in preserved ipsilateral breasts. After a median period of 4.1 years (range, years), 191 patients (90 %) with invasive breast tumor recurrence and 21 patients (10 %) with DIN recurrence were offered a second SLNB. The patients agreed to the procedure and gave informed consent. The demographic, clinical, and treatment-related variables included age at recurrence, histopathologic characteristics of primary and recurrent breast tumors, pathologic status of the first and second sentinel lymph nodes (SLNs), number of removed SLNs at both surgeries, time from primary intervention to IBTR, type of surgery, and type of radiation therapy delivered. To evaluate the feasibility of second SLNBs, success rates of the second lymphoscintigraphy, intraoperative identification of the second SLN, and percentage of extra-axillary drainages were considered. Breast Cancer Treatment The locoregional management of primary breast tumors consisted of lumpectomy quadrantectomy and SLNB. Local recurrences were managed with conservative surgery or mastectomy and a second SLNB. The decision between BCS and mastectomy was carefully considered, with patient preference and other clinical features such as tumor location, tumor size, and breast size taken into account. According to institutional protocols, the patients underwent complete ALND only when macrometastases were identified in SLNs. No further axillary surgery was performed for patients with negative SLNs, isolated tumor cells (ITCs) only, or micrometastases in SLNs. Systemic adjuvant therapies were chosen by using a multidisciplinary approach considering prognostic and predictive factors. A
3 2374 M. Intra et al. FIG. 1 Cumulative incidence of local recurrence, axillary recurrence and distant metastasis; disease free survival; overall survival after second sentinel node biopsy A Cumulative Incidence Cumulative incidence Local recurrence Axillary recurrence Distant metastasis Other event B Disease Free Survival Disease Free survival 0.0 Years from 2nd BLS Years from 2nd BLS C 1.0 Overall survival 0.0 Overall Survival Years from 2nd BLS total of 201 patients (185 with invasive carcinoma and 16 patients with grade 2 or 3 DIN) had received adjuvant radiotherapy at a standard dosage after their initial surgery. For 66 patients with a diagnosis of invasive BC, a full dose of intraoperative radiotherapy (corresponding to 21 Gy) was delivered, and four patients received a boost of intraoperative radiation therapy followed by external irradiation. For 11 patients with low-grade DIN, radiotherapy had not been performed. All the patients were clinically examined at 6-month intervals and underwent annual mammography with or without ultrasonography. All the patients were followed up for at least 1 year after the second surgery. Breast Cancer Outcomes We noted local and axillary failures, distant metastases (as first events), and patient deaths from medical records. Causes of death were categorized as breast cancer, other malignant tumors, and unknown cause. Overall survival (OS), diseasefree survival (DFS), and cumulative incidence of local relapse, axillary recurrence, distant metastasis, and other events at 5 years were assessed (Fig. 1). Lymphoscintigraphy and Histopathologic Examination of SLNs Lymphoscintigraphy was performed according to previously reported standard techniques. 1,8 All the patients were injected with less than 80 nm of human 99m Tc-labeled albumin nanocolloids (Nanocoll; Nycomed Amersham- Sorin, Saluggia, VC, Italy, and Nanoalbumon; Radiopharmacy Laboratory Ltd., Budaörs, Hungary) 1 day before surgery, with a median activity of 20 MBq in a volume of 0.2 ml. The injection type (subdermal or peritumoral) was selected according to the depth of the tumor. Planar scintigraphic scans of involved breasts and axillary regions were obtained min after administration of the radiotracer, and delayed images were acquired where necessary. At 2 20 h after the injection, SLNBs were performed, and an intraoperative gamma ray detection probe (Neoprobe 2000; Ethicon, Somerville, NJ, USA) was used during surgery to confirm locations of the sentinel nodes and to facilitate their removal. All nodes that had absorbed the radiotracer were removed and sent for histopathologic examination. All SLNs removed in the first and second procedures were examined as frozen sections according to previously described standard techniques. 1
4 Re-operative Sentinel Node Biopsy in Locally Breast Relapse 2375 TABLE 2 Clinicopathologic features of patient groups Variable Statistical Analysis Primary tumor (1st surgery) No. of patients Type of second surgery BCS and SLNB Mastectomy and SLNB 102 Mean tumor size (cm) Histologic SLN status Macrometastasis 0 25 Micrometastasis 14 8 ITC 2 1 Negative No. of LNs removed ? Histologic subtype Invasive ductal carcinoma Invasive lobular carcinoma Mixed carcinoma 4 3 Other invasive tumors DIN Grade Unknown ER/PgR status Negative/negative Positive/negative Positive/positive Unknown 4 3 HER2 status Positive Negative Missing 15 9 Ki67 \ [ Missing 7 8 Breast tumor recurrence (2nd surgery) BCS breast-conserving surgery, SLNB sentinel lymph node biopsy, ITC isolated tumor cells, LNs lymph nodes, DIN ductal intra-epithelial neoplasia, ER estrogen receptor, PgR progesterone receptor Exact 95 % confidence intervals (CIs) of proportions and rates were calculated using binomial and Poisson methods. The evaluated breast cancer end points included cumulative incidence of local, axillary, and distant recurrence as well as DFS, and OS. DFS was defined as the period from the second SLNBs to the first relapse including ipsilateral breast recurrence, contralateral breast cancer, appearance of second primary cancers, and death. OS was defined as the period from the second SLNBs until death from any cause. The causes of death were categorized as breast cancer, other malignant tumors, and unknown cause. Cumulative incidence functions were estimated according to the methods described by Kalbfleisch and Prentice, with competing causes of recurrence taken into account. 19 Estimates of DFS and OS functions were performed using the Kaplan-Meier method. All analyses were performed using SAS software (SAS Institute, Cary, NC, USA). RESULTS Patient Population and Tumor-Related Characteristics The clinical and histopathologic characteristics of the primary and recurrent tumors are listed in Table 2. As management for the recurrent tumors, mastectomy and a second conservative surgery were performed for 102 and 110 patients, respectively. Complete ALND was performed for 25 patients with macrometastatic SLNs. Second SLNBs were negative for 178 patients, and micrometastasis disease was identified in eight sentinel nodes. In one patient, ITCs were visualized in the sentinel node. Invasive and DIN relapses developed at recurrence for respectively 191 (90 %) and 21 patients (10 %). The median time between first surgery and IBTR was 4.1 years (range, years). The mean tumor size was 1.3 cm for the primary tumors and 1.1 cm for the IBTRs. The average number of nodes removed at first surgery was 1.7 (range, 1 7 nodes), and only 33 patients (16 %) had three or more lymph nodes removed. Feasibility of Second Sentinel Node Biopsy Technique For 207 of the 212 patients with IBTR, preoperative lymphoscintigraphy demonstrated at least one new axillary SLN (1 in 128 patients, 2 in 47 patients, and 3 or more in 25 patients). In 17 patients (8 %), additional extra-axillary aberrant drainages were observed in the contralateral axilla, intramammary, interpectoral, and internal mammary regions and in the infraclavicular fossa (Table 3). Aberrant drainage pathways were not routinely dissected. Only those accessible during surgery were removed. No metastases were found in the dissected aberrant drainages. Lymphoscintigraphy failed to identify any SLNs in five patients (2.3 %) but was successful for 207 patients (97.7 %; 95 % CI, %). Successful SLN biopsies
5 2376 M. Intra et al. TABLE 3 Sites and numbers of patients with aberrant drainage at second lymphoscintigraphy Site of aberrant drainage Contralateral axilla 6 Intramammary 4 Interpectoral region 4 Internal mammary 2 Infraclavicular fossa 1 Total 17 were performed for 196 of the 207 patients in whom lymphoscintigraphy identified at least one SLN. Isolation of SLNs from the remaining 11 patients could not be accomplished. In the vast majority of the patients (87 %), one or two SLNs were identified and removed. In 17 patients (8 %), three or more SLNs were identified at surgery, for an identification rate of 94.7 % (95 % CI, %). Breast Cancer Outcomes After a median follow-up period of 48 months (range, months; 95 % CI, months), the annual axillary recurrence rate was 0.8 %. The cumulative incidence of local recurrence at 5 years was 8.3 % (95 % CI, %), whereas the incidences of axillary recurrence, distant metastases, and other events were respectively 3.9 % (95 % CI, %), 4.7 % (95 % CI, %), and 3.2 % (95 % CI, %). Distant metastases occurred in ten patients (annual rate, 1.2 %; 95 % CI, %). Of these metastases, four were in bones, two were in the liver, three were multiple metastases, and one was of unknown location. In the entire cohort, 39 events were identified including breast-related events, second primary cancers, and deaths from other causes as the first event, with an annual event rate of 4.6 % (95 % CI, %). The 5-year DFS rate was 79.9 % (95 % CI, %). Overall, 12 of 212 patients (5.7 %) died after the second procedure (ten of breast cancer and two of unknown causes), for an annual mortality rate of 1.3 % (95 % CI, %). The 5-year OS was 93.9 % (95 % CI, %). DISCUSSION The main argument against second SLNB is that lymphatic channels and drainages are considered to be disrupted due to fibrosis after axillary surgery and radiotherapy, with potentially serious effects on lymphatic mapping at the time of recurrence. 15,20 23 However, after the disruption of lymphatic channels, a physiologic N restoration of the axilla s drainage anatomy (and that of other extra axillary locoregional nodes) occurs, rendering the aforementioned obstacle only temporary. Thus, the time between the first axillary surgery and the recurrence enables restoration of the lymphatic net, with new lymphatic bridges connecting the breast with the surgically managed axilla. This postoperative collateralization of lymphatics occurs as a physiologic compensatory mechanism, and new lymphatic pathways allow identification of novel SLNs as indicative of new tumors as the first SLN was for the first tumor. Thus, the logical argument against a second SLNB may paradoxically also be a strong argument in its favor, introducing a more dynamic concept of SLN: from one SLN forever to always a new SLN. 8,10,24 It is important to standardize the period between the first negative SLNB and the IBTR so that true second SLNs can be identified on lymphoscintigraphy. However, early recurrences (within the first 6 months) are conventionally considered as residual disease from the first tumor rather than true recurrences. In these cases, the first SLN retains its predictive value for both the first tumor and the early recurrence, and a second SLNB might not be indicated. The percentage of aberrant lymph drainage pathways outside the ipsilateral axilla in patients with previous BCS and SLNBs is %, 10 12,16,17 indicating a central role of preoperative lymphoscintigraphy for these patients. Although the rate of extra-axillary lymphatic drainage was quite low (8 %) in the current study, we recommend routine use of lymphoscintigraphy for SLNB. In a prospective study of 44 patients with recurrent breast cancer by Axelsson and Jonsson, 14 preoperative lymphoscintigraphy showed SLNs in 51 % of the patients. At the time of intervention, SLNs were located in 20 (45 %) of the 44 patients, corresponding to 83 % of patients with positive lymphoscintigraphy. To determine success rates for second SLNBs, both intraoperative identification of sentinel nodes and success rates for the second lymphoscintigraphy must be considered. However, in the absence of preoperative visualization of SLN on lymphoscintigraphy, our institutional policy is to consider axillary dissection only after a careful evaluation of all patient and tumor characteristics that increase axillary metastatic risk. The median number of axillary lymph nodes removed in the first surgery may be the most important factor for successful identification of SLNs during the second surgical intervention. Two publications from the Memorial Sloan-Kettering Cancer Center addressed the issue of second SLNBs in locally recurrent breast cancers. The authors of the first study 9 reported an overall SLN identification rate of 75 %. In contrast, the second paper, 10 which was an update of data from 117 patients with IBTR after BCS, reported an SLN identification rate of only 55 %,
6 Re-operative Sentinel Node Biopsy in Locally Breast Relapse 2377 possibly due to the inclusion of more patients with previous ALND. Second SLNBs failed for 39 (62 %) of 63 patients with previous ALND but for only 14 (26 %) of 54 patients with prior SLNBs (p = ). The authors concluded that the success rate for second SLNBs is inversely correlated with the number of lymph nodes removed at the first intervention and directly correlated with positive lymphoscintigraphy findings. 10 A recent systematic review and meta-analysis of 26 articles by Maaskant-Braat et al. 18 analyzed 692 patients with locally recurrent breast cancer who underwent second SLNBs. Of these patients, 301 had undergone previous SLNBs, 361 had undergone ALNDs, and 30 had undergone no previous surgical staging. The overall identification rate was 65.3 % (452 of 692 patients), but the rate was significantly higher (p \ ) for the patients who had undergone previous SLNBs (81.0 %, 243 of 301 patients) than for the patients who had undergone ALNDs (52.2 %, 166 of 318 patients). Aberrant drainage pathways were visualized in 43.2 % of these patients, which tended to be more frequent after ALND. The current study included only patients who had received a combination of BCS and SLNBs and showed a higher SLN identification rate. CONCLUSIONS The current study demonstrates an apparent rational basis for performing second SLNBs for IBTR patients previously treated with BCS who had negative SLNB results. The lymphoscintigraphic technique enables the most appropriate preoperative selection of patients for axillary and extra-axillary SLNB or ALND, thereby enabling optimal surgical programming and adequate preparation of patients. REFERENCES 1. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349: Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349: Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998; 339: Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347: Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24: Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2014;32: Burger AE, Pain SJ, Peley G. Treatment of recurrent breast cancer following breast-conserving surgery. Breast J. 2013;19: Intra M, Trifiro G, Galimberti V, et al. Second axillary lymph node biopsy for ipsilateral breast tumour recurrence. Br J Surg. 2007;94: Port ER, Fey J, Gemignani ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg. 2002;195: Port ER, Garcia-Etienne CA, Park J, Fey J, Borgen PI, Cody HS III. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol. 2007;14: van der Ploeg IM, Oldenburg HS, Rutgers EJ, et al. Lymphatic drainage patterns from the treated breast. Ann Surg Oncol. 2010;17: Cox CE, Furman BT, Kiluk JV, et al. Use of reoperative sentinel lymph node biopsy in breast cancer patients. J Am Coll Surg. 2008;207: Kaur P, Kiluk JV, Meade T, et al. Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection. Ann Surg Oncol. 2011;18: Axelsson CK, Jonsson PE. Sentinel lymph node biopsy in operations for recurrent breast cancer. Eur J Surg Oncol. 2008;34: Kothari MS, Rusby JE, Agusti AA, MacNeill FA. Sentinel lymph node biopsy after previous axillary surgery: a review. Eur J Surg Oncol. 2012;38: Schrenk P, Tausch C, Wayand W. Lymphatic mapping in patients with primary or recurrent breast cancer following previous axillary surgery. Eur J Surg Oncol. 2008;34: Maaskant-Braat AJ, Roumen RM, Voogd AC, Pijpers R, Luiten EJ, Rutgers EJ, Nieuwenhuijzen GA. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol. 2013;20: Maaskant-Braat AJ, Voogd AC, Roumen RM, Nieuwenhuijzen GA. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2013;138: Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34: Dinan D, Nagle E, Pettinga J. Lymphatic mapping and sentinel node biopsy in women with an ipsilateral second breast carcinoma and a history of breast and axillary surgery. Am J Surg. 2005;190: Newman EA, Cimmino VM, Sabel MS, Diehl KM, Frey KA, Chang AE, Newman LA. Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer. Surg Clin North Am. 2007;87: Maaskant-Braat AJ, de Bruijn SZ, Woensdregt K, Pijpers H, Voogd AC, Nieuwenhuijzen GA. Lymphatic mapping after previous breast surgery. Breast. 2012;21: Boughey JC, Ross MI, Babeira GV, et al. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer. 2007;7: Taback B, Nguyen P, Hansen N, Edwards GK, Conway K, Giuliano AE. Sentinel node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol. 2006;13:
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationImpact of radiation therapy on survival in patients with triple negative breast cancer
548 Impact of radiation therapy on survival in patients with triple negative breast cancer LAUREN T. STEWARD 1, FENG GAO 2, MARIE A. TAYLOR 3 and JULIE A. MARGENTHALER 1 1 Department of Surgery; 2 Division
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationPostoperative radiotherapy after conservative surgery for early breast cancer: 5-year results
Original article UDC: 618.19-006:849.1:616-089.8 Arch Oncol 2004;12(1):29-33. Postoperative radiotherapy after conservative surgery for early breast cancer: 5-year results Jasmina MLADENOVIÆ Marko DO IÆ
More informationSurvival and axillary recurrence following sentinel nodepositive breast cancer without completion axillary lymph node dissection the SENOMAC trial.
Survival and axillary recurrence following sentinel nodepositive breast cancer without completion axillary lymph node dissection the SENOMAC trial. A randomized study of patients with sentinel node macrometastasis
More informationDuctal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194
Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194 Sabin B. Motwani, MD 1 ; Sharad Goyal, MD 1 ; Meena S. Moran, MD 2 ; Arpit Chhabra, BS
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationAxillary Ultrasonography in Breast Cancer Patients Helps in Identifying Patients Preoperatively with Limited Disease of the Axilla
Ann Surg Oncol DOI 10.1245/s10434-014-3674-x ORIGINAL ARTICLE BREAST ONCOLOGY Axillary Ultrasonography in Breast Cancer Patients Helps in Identifying Patients Preoperatively with Limited Disease of the
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationGuidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
More informationLymphatic Mapping Techniques and Sentinel Lymph Node Biopsy in Breast Cancer
Surg Clin N Am 87 (2007) 353 364 Lymphatic Mapping Techniques and Sentinel Lymph Node Biopsy in Breast Cancer Erika A. Newman, MD a, Lisa A. Newman, MD, MPH, FACS b, * a Department of Surgery, University
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationBasics and limitations of adjuvant online an internet based decision tool
Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies
More informationIpsilateral In-Breast Tumor Relapse after Breast Conservation Therapy: True Recurrence Versus New Primary Tumor
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No., September: 18-19, 6 Ipsilateral In-Breast Tumor Relapse after Breast Conservation Therapy: True Recurrence Versus New Primary Tumor HASSAN M. ABD-ALLA,
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationPATIENT SUBSETS WITH T1-T2, NODE-NEGATIVE BREAST CANCER AT HIGH LOCOREGIONAL RECURRENCE RISK AFTER MASTECTOMY
doi:10.1016/j.ijrobp.2004.09.013 Int. J. Radiation Oncology Biol. Phys., Vol. 62, No. 1, pp. 175 182, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front
More informationBreast Cancer - Do You Know the Race of Her2?
DOI 10.1186/s40064-015-1538-x RESEARCH Open Access Her2 positivity and race predict higher mastectomy rates: a SEER database analysis Theresa L. Schwartz 1, Jula Veerapong 1 and Leslie Hinyard 2* Abstract
More informationArticles. Early Breast Cancer Trialists Collaborative Group (EBCTCG)* www.thelancet.com Vol 366 December 17/24/31, 2005 2087
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationOutcome analysis of breast cancer patients who declined evidence-based treatment
Joseph et al. World Journal of Surgical Oncology 2012, 10:118 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Outcome analysis of breast cancer patients who declined evidence-based treatment Kurian
More informationReview of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project
Surg Clin N Am 87 (2007) 279 305 Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project Lisa A. Newman, MD, MPH, FACS a, *, Eleftherios P. Mamounas, MD, MPH,
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationBreast cancer in women diagnosis, treatment and follow-up
Breast cancer in women diagnosis, treatment and follow-up H. WILDIERS, S. STORDEUR, J. VLAYEN, R. SCHOLTEN, F. VAN DE WETERING, C. BOURGAIN, B. CARLY, MR. CHRISTIAENS, V. COCQUYT, E. LIFRANGE, JC. SCHOBBENS,
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationSanta Maria Annunziata Hospital / Azienda Sanitaria di Firenze
- Firenze, Italy General Information New breast cancer cases treated per year 350 Breast multidisciplinarity team members 12 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationHereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center
Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt
More informationPrognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
Original Study Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy Sota Asaga, Takayuki Kinoshita, Takashi Hojo, Junko Suzuki, Kenjiro Jimbo, Hitoshi
More informationThe Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Invasive Breast Cancer in the Post-ACOSOG Z0011 Trial Era
Ann Surg Oncol DOI 10.1245/s10434-014-4071-1 ORIGINAL ARTICLE BREAST ONCOLOGY The Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Invasive Breast Cancer in the Post-ACOSOG Z0011 Trial
More informationElioTanaka, MD, Medical Oncology, Audit Medical in Health Service, Curitiba s Health Institute, Paraná, Brazil. www.isaebrasil.com.
IP2: The cost-effectiveness of breast magnetic resonance imaging (MRI) to detect a locoregional recurrence in patients with breast conserving therapy. Is it feasible in Latin America? www.isaebrasil.com.br
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationManagement of Ductal Carcinoma in Situ of the Breast
Evidence-based Series 1-10 Version 2.2006 IN REVIEW A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Management of Ductal Carcinoma in Situ of the Breast W.
More informationPublished Ahead of Print on September 16, 2013 as 10.1200/JCO.2013.49.5077. J Clin Oncol 31. 2013 by American Society of Clinical Oncology
Published Ahead of Print on September 16, 213 as 1.12/JCO.213.49.577 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.213.49.577 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationHelen Joseph Breast Care Clinic - Johannesburg, South Africa
- Johannesburg, South Africa General Information New breast cancer cases treated per year 360 Breast multidisciplinarity team members 12 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationAzienda Ospedale Annunziata Cosenza - Cosenza, Italy
- Cosenza, Italy General Information New breast cancer cases treated per year 180 Breast multidisciplinarity team members 9 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationUnderstanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationSignificance of Sentinel Lymph Node Micrometastases in Human Breast Cancer
Significance of Sentinel Lymph Node Micrometastases in Human Breast Cancer Charles E Cox, MD, FACS, John V Kiluk, MD, Adam I Riker, MD, FACS,JohnMCox,MD, Nathon Allred, BA, Daniel C Ramos, BS, Elisabeth
More informationOutcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy
ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More information- Pisa, Italy. Azienda Ospedaliero-Universitaria Di Pisa - Ospedale S. Chiara 1/6. General Information
- Pisa, Italy General Information New breast cancer cases treated per year 500 Breast multidisciplinarity team members 18 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists and
More informationWhat Every General Surgeon Should Know About Breast Cancer
What Every General Surgeon Should Know About Breast Cancer Christina A. Finlayson, MD Associate Professor, Surgery Director, University of Colorado Hospital Breast Center Outline How are we doing in the
More informationHow To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
More informationDoes Resection of an Intact Breast Primary Improve Survival in Metastatic Breast Cancer?
rvival in Metastatic Breast Cancer? Review Article [1] July 01, 2007 By Seema A. Khan, MD [2] The recommended primary treatment approach for women with metastatic breast cancer and an intact primary tumor
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval U.S. Department of Health and Human
More informationBreast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report
Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT Five-year report Community Health Pathology Southern Area Health Service ACT Health General Practitioners Nurses Social
More informationCorporate Medical Policy Brachytherapy Treatment of Breast Cancer
Corporate Medical Policy Brachytherapy Treatment of Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_treatment_of_breast_cancer 7/1996 5/2015 5/2016 5/2015
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationAzienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi - Bologna, Italy
Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi - Bologna, Italy General Information New breast cancer cases treated per year 284 Breast multidisciplinarity team members 14 Radiologists,
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: February 24, 2012 Revised:
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [For the list of services and procedures that need preauthorization, please refer to www.mcs.pr Go to Comunicados a Proveedores, and click
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationBreast Cancer Accelerated Partial Breast Irradiation Bruce G. Haffty, MD Professor and Chairman Dept Radiation Oncology UMDNJ-RWJMS Cancer Institute
Breast Cancer Accelerated Partial Breast Irradiation Bruce G. Haffty, MD Professor and Chairman Dept Radiation Oncology UMDNJ-RWJMS Cancer Institute of New Jersey Rationale for Partial Breast Radiation
More informationThe University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast
The American Journal of Surgery 186 (2003) 337 343 Scientific paper The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast Melvin J. Silverstein, M.D.*
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationTHREE EVENTS OCCURRED during the 1980s that
Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less By Bernard Fisher, John Bryant,
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of highdose chemotherapy for breast cancer patients Marino P, Siani C, Roche H, Moatti J P Record Status This is a critical
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationManagement of Early Breast Cancer
Management of Early Breast Cancer Evidence-based Best Practice Guideline Management of Early Breast Cancer Evidence-based Best Practice Guideline Ministry of Health 2009 Published by: New Zealand Guidelines
More informationThe lymphatic system consists of a network of vessels
IMAGING Whole-Body Lymphoscintigraphy Using Transmission Scans Martha Vallejo Mar, BBA, CNMT; Sonia Gee-Johnson, BS, CNMT; E. Edmund Kim, MD; and Donald A. Podoloff, MD Department of Nuclear Medicine,
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationWhat Every General Surgeon Should Know About Breast Cancer
What Every General Surgeon Should Know About Breast Cancer Christina A. Finlayson, MD Associate Professor, Surgery Director, University of Colorado Hospital Breast Center Outline How are we doing in the
More informationOriginal Article. Shanghai, China; University Shanghai, China. The first 2 authors contributed equally to this work.
Analysis in Early Stage Triple-Negative Breast Cancer Treated With Mastectomy Without Adjuvant Radiotherapy: Patterns of Failure and Prognostic Factors Xingxing Chen, MD 1,2 ; Xiaoli Yu, MD 1,2 ; Jiayi
More informationSBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX
SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX SAM Session 2 Friday, April 8 2.5 SAM Credits Thank you for completing this SAM activity. Below you will find correct responses, rationales,
More informationAmerican College of Radiology ACR Appropriateness Criteria DUCTAL CARCINOMA IN SITU
American College of Radiology ACR Appropriateness Criteria Date of origin: 1996 Last review date: 2014 DUCTAL CARCINOMA IN SITU Expert Panel on Radiation Oncology Breast: Seth A. Kaufman, MD 1 ; Eleanor
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationORIGINAL ARTICLE THORACIC ONCOLOGY
Ann Surg Oncol (2013) 20:1934 1940 DOI 10.1245/s10434-012-2800-x ORIGINAL ARTICLE THORACIC ONCOLOGY Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationAZ Sint Lucas - Brugge, Belgium
- Brugge, Belgium General Information New breast cancer cases treated per year 150 Breast multidisciplinarity team members 12 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More information